Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

imatinib (YD312)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

YD Global

Drug class:

c-KIT inhibitor, SCF signal transduction pathway inhibitor

Related drugs:

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2	YD312 Sensitive: A2 - Guideline YD312 Sensitive : A2
SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	binimetinib + YD312 Sensitive: A2 - Guideline binimetinib + YD312 Sensitive : A2	binimetinib + YD312 Sensitive: A2 - Guideline binimetinib + YD312 Sensitive : A2
G0S2 overexpression	Chronic Myeloid Leukemia	G0S2 overexpression	Chronic Myeloid Leukemia	YD312 Sensitive: C3 – Early Trials YD312 Sensitive : C3	YD312 Sensitive: C3 – Early Trials YD312 Sensitive : C3
DNMT3A mutation	Chronic Myeloid Leukemia	DNMT3A mutation	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
ASXL1 mutation	Chronic Myeloid Leukemia	ASXL1 mutation	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
KMT2D underexpression	Chronic Myeloid Leukemia	KMT2D underexpression	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
XPC K939G	Chronic Myeloid Leukemia	XPC K939G	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
XPC K939G + XPC A499V	Chronic Myeloid Leukemia	XPC K939G + XPC A499V	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
SLC22A1 1222AG	Chronic Myeloid Leukemia	SLC22A1 1222AG	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
SLCO1B3 334TT	Chronic Myeloid Leukemia	SLCO1B3 334TT	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3